Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 73% of modeled bridge. Strengths: Occupancy Rate. Risks: Bed Count. Risk-adjusted uplift: $25.5M (vs $34.8M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $13.2M | $13.2M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $12.7M | $364K | $13.1M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $2.0M | $6.0M | $8.1M | $25.4M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $424K | $424K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 25.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $3.3M | $6.6M | $9.9M | $13.2M | $13.2M | $13.2M | $13.2M |
| Denial Rate Reduction | $0 | $3.3M | $6.6M | $9.8M | $13.1M | $13.1M | $13.1M | $13.1M |
| A/R Days Reduction | $0 | $2.7M | $5.4M | $8.1M | $8.1M | $8.1M | $8.1M | $8.1M |
| Clean Claim Rate | $0 | $212K | $424K | $424K | $424K | $424K | $424K | $424K |
| Cumulative | $0 | $9.5M | $19.0M | $28.2M | $34.8M | $34.8M | $34.8M | $34.8M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $34.8M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 54% / 8.8x | 59% / 10.1x | 63% / 11.5x | 65% / 12.1x | 67% / 12.8x |
| 9.0x | 49% / 7.5x | 54% / 8.6x | 58% / 9.8x | 60% / 10.4x | 62% / 11.0x |
| 10.0x | 45% / 6.4x | 49% / 7.5x | 54% / 8.5x | 55% / 9.1x | 57% / 9.6x |
| 11.0x | 41% / 5.5x | 45% / 6.5x | 49% / 7.5x | 51% / 7.9x | 53% / 8.4x |
| 12.0x | 37% / 4.8x | 41% / 5.7x | 46% / 6.6x | 48% / 7.0x | 49% / 7.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 12% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.7x, adding 2.8 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $71.5M | — | $71.5M | 10.8% |
| Year 1 | $73.6M | +$23.2M | $96.8M | 14.6% |
| Year 2 | $75.8M | +$34.8M | $110.7M | 16.7% |
| Year 3 | $78.1M | +$34.8M | $112.9M | 17.1% |
| Year 4 | $80.5M | +$34.8M | $115.3M | 17.4% |
| Year 5 | $82.9M | +$34.8M | $117.7M | 17.8% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $6.6M | $9.9M | $13.2M | $15.9M |
| Denial Rate Reductio | $6.6M | $9.8M | $13.1M | $15.7M |
| A/R Days Reduction | $4.0M | $6.0M | $8.1M | $9.7M |
| Clean Claim Rate | $212K | $318K | $424K | $508K |
| Total | $17.4M | $26.1M | $34.8M | $41.8M |
Peer Context — Where This Hospital Sits
Key metrics vs 113 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 10.8% | -7.9% | 4.8% | 14.7% | P63 |
| Net-to-Gross | 17.3% | 12.7% | 18.1% | 25.0% | P45 |
| Occupancy | 84.1% | 57.7% | 68.4% | 77.6% | P88 |
| Rev/Bed | $1.9M | $1.0M | $1.3M | $1.6M | P88 |
| Exp/Bed | $1.7M | $895K | $1.2M | $1.6M | P81 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.